Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) stock advanced by 2.56% to $9.21 on a strong trading day, outperforming the NASDAQ Composite Index and the Dow Jones Industrial Average. The company's stock closed 23.06% below its 52-week high of $11.97, achieved on February 26th. This performance occurred during a favorable market session where major indices also saw gains.
Novavax Inc. stock underperforms Thursday when compared to competitors
Novavax Inc. (NVAX) stock fell by 3.13% on Thursday, closing at $8.98, despite an overall positive trading day for the broader market indices like the NASDAQ Composite and Dow Jones Industrial Average. The company's shares are currently trading 24.98% below their 52-week high of $11.97, which was reached on February 26th.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) saw its stock increase by 4.16% to $9.27, outperforming major indices like the NASDAQ Composite and the Dow Jones Industrial Average. This rise broke a three-day losing streak for the company. The positive trading session saw the NASDAQ Composite rise 1.54% and the Dow Jones Industrial Average increase by 1.31%.
Novavax Inc. stock underperforms Monday when compared to competitors
Novavax Inc. (NVAX) shares experienced a 1.43% decline on Monday, closing at $8.93. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the NASDAQ Composite Index falling. This marks the second consecutive day of losses for Novavax stock.
Why (NVAX) Price Action Is Critical for Tactical Trading
This article analyzes Novavax Inc. (NVAX) using AI models, highlighting a weak near-term sentiment but strong mid and long-term outlooks. It presents three institutional trading strategies, including position trading, momentum breakout, and risk hedging, to capitalize on NVAX's potential movements. The analysis emphasizes risk-reward setups and multi-timeframe signal analysis for tactical trading decisions.
Novavax Inc stock (US66987V1098): earnings volatility and Covid-vaccine hopes in focus
Novavax Inc's stock is experiencing volatility following its latest quarterly figures and updated Covid-19 vaccine strategy. The company, known for its protein-based vaccines, is navigating a shift from mass vaccination campaigns to seasonal booster markets, requiring a focus on cost reduction and diversification into broader respiratory and combination vaccines. Investors are keenly watching its ability to compete in the US seasonal respiratory vaccine market and secure future partnerships.
Novavax, Inc. Trade Ideas — BOATS:NVAX
This article compiles various trade ideas and analyses for Novavax (NVAX) from different traders on TradingView. The commentary covers both technical and fundamental aspects, discussing the company's cyclical nature, strategic efforts to improve commercial performance, resolution of the Gavi dispute, and long-term prospects including new vaccine developments. While some analysts are bullish on NVAX's potential for significant gains, others highlight risks associated with its price volatility and upcoming earnings reports.
Novavax Inc stock (US6707721049): vaccine specialist in focus after latest COVID shot update
Novavax Inc. remains a key focus for investors as it updates on its latest protein-based COVID-19 vaccine and funding. The company aims to stabilize its business after the pandemic and shift towards a sustainable seasonal model, emphasizing updated vaccine formulations and combination shots for COVID-19 and influenza. Its future success hinges on regulatory decisions, seasonal demand, and diversification beyond its primary COVID vaccine product.
Novavax stock (US66987V1098): vaccine maker faces fresh focus after recent company updates
Novavax (NVAX) is under renewed scrutiny by investors due to recent company updates concerning its vaccine pipeline, cash position, and commercial outlook. The company's focus on respiratory vaccine demand and regulatory milestones makes it relevant for US investors. Novavax's business model, heavily reliant on protein-based vaccines and subject to rapid shifts in public health recommendations, leads to high stock volatility and close investor monitoring of product sales, collaboration revenue, and operating cash use.
Shah Capital holds 9% Novavax stake and challenges board (NVAX)
Shah Capital Management and its affiliates disclosed a 9.03% stake in Novavax (NVAX) and formally challenged the company's leadership. The group, which beneficially owns 14.84 million shares, sent a presentation to Novavax's board on May 14, 2026, outlining what they perceive as failures in marketing, the Sanofi partnership, capital markets activity, and leadership focus. This move indicates their role as an engaged and critical shareholder rather than a passive investor, with no change in their economic position since the previous filing.
Novavax Inc. stock underperforms Friday when compared to competitors
Novavax Inc. (NVAX) stock fell 3.10% on Friday to $9.06, underperforming the broader market indexes like the NASDAQ Composite and Dow Jones Industrial Average. The company's stock closed significantly below its 52-week high, reached in February.
Shah Capital Management Sent a Presentation to the Board of Novavax, Inc
Shah Capital Management sent a presentation titled "Elevating Novavax" to Novavax Inc.'s board of directors on May 14, 2026. The presentation outlined perceived failures of the current leadership, including marketing issues since 2023, an underwhelming Sanofi partnership, capital market mismanagement, and leadership enriching itself instead of building value. This action highlights ongoing shareholder activism regarding Novavax's performance.
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know
The article focuses on Novavax, Inc. (NVAX) and its recent stock market activity, highlighting its noticeable price change and robust trading volume. It advises investors to look beyond short-term stock movements and delve into the company's fundamentals and future prospects. The piece suggests that understanding these underlying factors is key to making informed investment decisions regarding NVAX.
Novavax Inc. stock outperforms competitors on strong trading day
Shares of Novavax Inc. (NVAX) advanced 1.30% to $9.35, outperforming the broader market on a strong trading day where both the NASDAQ Composite Index and Dow Jones Industrial Average saw significant gains. Despite this rise, Novavax Inc. closed 21.89% short of its 52-week high.
Vanguard Group Inc. Has $103.96 Million Position in Novavax, Inc. $NVAX
Vanguard Group Inc. significantly increased its stake in Novavax, Inc. during the fourth quarter, now owning 9.52% of the company worth over $103 million. This increase follows Novavax's better-than-expected Q1 earnings, which helped fuel a recent stock rally despite mixed analyst sentiments. The article highlights key news driving Novavax's stock performance and institutional investor activity.
Novavax Inc. stock underperforms Wednesday when compared to competitors
Novavax Inc. (NVAX) shares fell by 4.05% on Wednesday, closing at $9.23, even as the NASDAQ Composite Index rose. The stock underperformed its competitors and the broader market, which experienced mixed trading. Novavax is currently 22.89% below its 52-week high of $11.97, reached on February 26th.
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb
Shares of Moderna and Novavax rose following renewed concerns over a hantavirus outbreak connected to the MV Hondius cruise ship, prompting some traders to invest in vaccine-related stocks. Moderna is reportedly engaged in early-stage research for hantavirus vaccines, while Novavax experienced a sympathy bid. Despite the rally, analysts caution that the commercial opportunity for a hantavirus vaccine may be limited due to the rarity of outbreaks and long development timelines.
Novavax Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Novavax Inc.'s stock (NVAX) advanced 1.26% on Tuesday, closing at $9.62. Despite this gain, the stock underperformed compared to its competitors amidst a mixed trading session where the Dow Jones Industrial Average rose and the NASDAQ Composite Index fell. NVAX is currently 19.63% below its 52-week high reached in February.
Novavax Bets on Turnaround Momentum Following Pfizer Partnership
Novavax is aiming to reposition itself as a growth company in the vaccine and biotechnology sector following a strong first quarter and an expanded partnership with Pfizer. The company's stock has surged over 50% year-to-date due to renewed interest in infectious disease preparedness and potential royalty streams from its collaboration with Pfizer. Despite challenges with profitability and debt, Wall Street analysts see significant upside potential if Novavax can successfully execute on its partnerships and product development.
Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes
Novavax stock (NVAX) has seen a significant rally this year due to licensing agreements and a better-than-expected Q1 earnings report, showing a smaller loss and higher revenue than anticipated. Despite this recent surge, which has led to a 59% performance over 52 weeks, the stock is still down over 92% in the past five years. Technical indicators suggest a strong buy for NVAX, but options data, particularly volatility skew, indicates that "smart money" is focused on downside protection rather than forecasting further upside, suggesting the stock may be a risky lottery ticket rather than a sound long-term investment.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) stock rallied 9.53% to $10.11 on a strong trading day, outperforming the NASDAQ Composite Index and the Dow Jones Industrial Average. The company's stock closed 15.54% below its 52-week high of $11.97, achieved on February 26th. This performance occurred amidst a positive overall market session.
Novavax Stock Jumps As Pfizer Deal And Q1 Beat Energize Traders
Novavax Inc. (NASDAQ: NVAX) stock soared by 13.98% following a strong Q1 2026 earnings report and positive developments with its COVID-19 vaccine technology. The company reported revenue significantly above consensus and a narrower loss per share, driven by a licensing deal with Pfizer for its Matrix-M adjuvant technology and an expanded partnership with Sanofi. This shift in narrative from a struggling COVID-19 vaccine company to a platform-and-partners model has energized traders, despite ongoing negative equity and cash burn concerns.
[144] NOVAVAX INC SEC Filing
NOVAVAX INC (NVAX) has filed a Form 144 Notice of Proposed Sale of Securities with the SEC. The filing indicates a proposed sale of 30,000 common shares acquired through stock plan activity, with an aggregate market value of $296,083, to be sold on NASDAQ via Merrill Lynch. This filing is classified as neutral in both impact and sentiment.
Novavax to Participate in BofA Securities 2026 Health Care Conference
Novavax, Inc. announced its participation in the BofA Securities 2026 Health Care Conference. A fireside chat featuring Novavax is scheduled for Wednesday, May 13, 2026, at 3:00 – 3:30 p.m. Pacific Time in Las Vegas, NV, and will be webcast live. The company will also hold investor meetings on the same day.
Novavax Inc. stock underperforms Thursday when compared to competitors
Novavax Inc. (NVAX) shares fell 1.39% on Thursday, closing at $9.23, amid a general market decline with the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing losses. This drop ended a two-day winning streak for the company's stock. The stock's performance indicates it underperformed compared to its competitors during this trading session.
Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat
Novavax's stock jumped after reporting first-quarter revenue of $139.5 million, significantly beating analysts' estimates, primarily due to licensing and supply payments for its Matrix-M adjuvant technology. This financial pivot, driven by a key deal with Pfizer and an existing partnership with Sanofi, signals a strategic shift from direct COVID-19 vaccine sales to a licensing model. The company aims for greater insulation from market volatility and is also developing a C. difficile vaccine candidate, targeting profitability around 2028.
Novavax to Participate in BofA Securities 2026 Health Care Conference
Novavax, Inc. announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 13, 2026, in Las Vegas, NV. The company will hold a fireside chat and investor meetings. A webcast of the fireside chat will be available on Novavax's investor relations website, with a replay accessible for 30 days.
Q1 2026 Novavax Inc Earnings Call Transcript
This article provides the transcript for Novavax Inc.'s Q1 2026 earnings call, held on May 6, 2026. The call details the company's financial results and operational highlights for the first quarter of 2026, featuring an introduction by Jim Kelly, Executive Vice President and Chief Financial Officer. The transcript also lists various past and future earnings calls and conference transcripts for Novavax Inc.
Novavax, Inc. (NASDAQ:NVAX) Q1 2026 Earnings Call Transcript
Novavax (NASDAQ:NVAX) reported its Q1 2026 earnings, highlighting significant progress in its new strategy focused on partnering its Matrix-M technology, capital-efficient R&D, and a lean operating model. The company announced new partnerships and material transfer agreements (MTAs) with major pharmaceutical companies, targeting over 30 unique indications in infectious diseases and oncology. Novavax also reiterated its full-year 2026 revenue guidance and detailed its path towards profitability by 2028, driven by milestone payments and royalties from collaborations.
Novavax Inc 1Q 2026: Revenue $139.51M, EPS ($0.06) — 10-Q Summary
Novavax Inc (NVAX) reported its first-quarter 2026 results, with revenue significantly declining to $139.51 million and a net loss of $9.49 million, resulting in a diluted EPS of ($0.06). The decline was attributed to a shift in product mix and lower Nuvaxovid volumes. Despite financial setbacks, the company highlighted progress in partnerships, product development, and operational changes aimed at cost reduction and pipeline advancement.
Why Novavax (NVAX) Is Up 17.4% After Q1 2026 Revenue Plunge And Profit Swing To Loss
Novavax (NVAX) saw its stock rise by 17.4% despite a significant revenue plunge in Q1 2026 and a swing to a net loss. The company reported US$139.51 million in revenue, down from US$666.66 million a year prior, and a net loss of US$9.49 million. This performance highlights the shift in Novavax's business model towards an asset-light, partnership-driven approach, relying on licensing deals and future milestone payments to fund operations.
Why Novavax Stock Is Trading Higher On Wednesday? - Novavax (NASDAQ:NVAX)
Novavax stock is trading higher after reporting better-than-expected first-quarter financial results. The company exceeded sales estimates and highlighted a strengthened balance sheet with a new credit facility, alongside strategic partnerships aimed at long-term growth. Novavax reaffirmed its 2026 sales guidance, and its technical analysis suggests easing downside pressure.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares rose significantly on a strong trading day for the overall stock market. The stock gained 15.56%, closing at $9.36, while the NASDAQ Composite and Dow Jones Industrial Average also saw considerable increases. This marks the second consecutive day of gains for Novavax stock.
Earnings Flash (NVAX) Novavax, Inc. Reports Q1 Revenue $139.5M, vs. FactSet Est of $79.8M
Novavax, Inc. (NVAX) reported its first-quarter revenue of $139.5 million, significantly exceeding the FactSet estimate of $79.8 million. The company, a biotechnology firm specializing in vaccine development, provided this financial update, highlighting its performance against analyst expectations. The article also touches on recent news items concerning Novavax's COVID vaccine and executive changes.
NOVAVAX ($NVAX) Releases Q1 2026 Earnings
NOVAVAX ($NVAX) announced its Q1 2026 earnings, reporting -$0.06 per share, significantly beating analyst estimates of -$0.23. The company also surpassed revenue expectations with $139,510,000 against an estimated $79,889,286. The article also provides details on hedge fund activity, showing both increases and decreases in institutional holdings, and a summary of recent analyst ratings and price targets for NVAX.
Novavax (NASDAQ: NVAX) posts Q1 loss, highlights Pfizer Matrix-M deal
Novavax reported a Q1 2026 net loss of $9.5 million and significantly reduced revenue of $140 million, primarily due to unusually high non-cash Nuvaxovid sales in the prior year. The company emphasized its strategic shift towards partnerships, particularly highlighting a new $30 million upfront payment from Pfizer for its Matrix-M adjuvant technology. Novavax reiterated its full-year 2026 financial guidance, focusing on cost reductions and establishing partnerships across infectious disease and oncology.
Novavax: Q1 Earnings Snapshot
Novavax Inc. (NVAX) reported a first-quarter loss of $9.5 million, or 6 cents per share, which was better than Wall Street's expectation of a 25 cent loss per share. The vaccine maker achieved revenue of $139.5 million for the period. These results were generated by Automated Insights using data from Zacks Investment Research.
Novavax beats first-quarter revenue estimates on strength in vaccine deals
Novavax exceeded first-quarter revenue estimates, driven by milestone payments from vaccine supply and licensing deals, which helped to offset declining demand for its COVID-19 vaccine. The company's strategy focuses on licensing its vaccine technology and Matrix-M adjuvant to other pharmaceutical companies, partially insulating it from policy uncertainties and late-stage development costs. Novavax maintained its full-year adjusted revenue forecast and continues to cut costs while facing pressure from activist investor Shah Capital.
Novavax: Q1 Earnings Snapshot
Novavax Inc. (NVAX) reported a first-quarter loss of $9.5 million, or 6 cents per share, which exceeded Wall Street expectations. Analysts surveyed by Zacks Investment Research had estimated a loss of 25 cents per share. The vaccine maker also posted revenue of $139.5 million for the quarter.
Novavax (NVAX) Q1 Earnings Report Preview: What To Look For
Novavax (NVAX) is set to report its Q1 earnings, with analysts expecting an 88.7% year-on-year revenue decline. Despite beating revenue and EPS estimates last quarter, the company has frequently missed Wall Street's revenue forecasts in the past two years. Peers like Moderna and Biogen have reported positive Q1 results, while Novavax's share price has seen a modest 1.6% increase over the last month, heading into earnings with an average analyst price target of $14.00 against a current share price of $8.09.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares rose 1.45% to $8.04 on Friday, outperforming the mixed trading session where the NASDAQ Composite Index rose and the Dow Jones Industrial Average fell. The stock closed 32.83% below its 52-week high of $11.97, which was reached on February 26th. The article reports on the company's stock performance relative to the broader market.
Vanguard reports 8.31M-share stake in Novavax (NVAX)
Vanguard Capital Management has reported a beneficial ownership of 8,305,681 shares, or 5.09%, of Novavax (NVAX) common stock via a Schedule 13G SEC filing. The filing indicates Vanguard has sole dispositive power over all these shares and sole voting power over 1,175,534 shares. These holdings include shares managed for Vanguard funds and other accounts, confirming Vanguard's significant but passive investment in Novavax.
Novavax investors get first-quarter 2026 results at 8:30 a.m. May 6
Novavax (Nasdaq: NVAX) will report its first-quarter 2026 financial results and operational highlights on May 6, 2026, at 8:30 a.m. ET. A live webcast and conference call will be available, with replay access provided for both phone and webcast. The announcement includes detailed instructions for registration, dial-in numbers, and replay access for investors.
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
Novavax, Inc. (Nasdaq: NVAX) has announced that it will report its first-quarter 2026 financial results and operational highlights on Wednesday, May 6, 2026, at 8:30 a.m. ET. The company will host a conference call for investors and media to discuss these results, with replay options available for a limited time afterward. Details for registering for the call and accessing the webcast have been provided.
Novavax (NVAX) director exercises RSUs for 9,520 common shares
Novavax Inc. director Charles W. Newton acquired 9,520 common shares through the exercise of Restricted Stock Units (RSUs) on April 25, 2026. These RSUs vest in three equal annual installments beginning April 25, 2025, contingent on his continued service on the Board of Directors. Following this transaction, Newton directly holds 9,520 common shares.
Novavax Inc. stock underperforms Tuesday when compared to competitors
Novavax Inc. (NVAX) shares dropped 1.86% to $7.92 on Tuesday, experiencing its second consecutive day of losses. This underperformance occurred during a generally poor trading session, with the NASDAQ Composite Index falling 0.90% and the Dow Jones Industrial Average dipping 0.05%. The company's stock declined relative to its competitors and broader market indices.
Novavax Inc. stock underperforms Monday when compared to competitors
Novavax Inc. (NVAX) shares dropped 1.82% to $8.07 on Monday, underperforming a mixed trading session for the broader market. Despite the NASDAQ Composite Index rising, Novavax closed significantly below its 52-week high.
Bank of America reports 4.1% Novavax stake (NASDAQ: NVAX)
Bank of America Corporation has filed an amendment to a Schedule 13G, revealing a beneficial ownership of 6,655,398 shares in Novavax Inc. This stake represents 4.1% of the class, calculated based on 162,935,945 outstanding shares as of February 16, 2026. The filing indicates shared voting power of 6,653,929 shares and shared dispositive power of 6,655,398 shares across Bank of America and its subsidiaries, clarifying that this is a passive disclosure and not an acquisition statement.
Novavax (NASDAQ: NVAX) details 2026 proxy, board slate and equity share increases
Novavax's 2026 proxy statement outlines key proposals for its upcoming annual meeting, including the election of three Class I directors, an advisory "say-on-pay" vote for executive compensation, and the ratification of Ernst & Young LLP as auditor. The company also seeks to increase its equity share plans by adding 9.4 million shares to its 2015 Stock Incentive Plan and 1 million shares to its Employee Stock Purchase Plan. Financially, Novavax reported $1.1 billion in total revenue for 2025, a 42% reduction in non-GAAP combined R&D and SG&A expenses, and a year-end cash position of $857 million, reflecting progress in its strategic transformation and partnership execution.
Avoiding Lag: Real-Time Signals in (NVAX) Movement
This article from Stock Traders Daily analyzes Novavax Inc. (NVAX), highlighting a weak near-term sentiment but strong mid and long-term signals. It presents various AI-generated trading strategies, including position trading, momentum breakout, and risk hedging, along with detailed support and resistance levels across different time horizons. The analysis emphasizes an exceptional risk-reward setup, targeting a significant gain with minimal risk.
